Tyligand Bioscience appoints Dr. Cong Lei as Sr. VP of Clinical Development
Tyligand Bioscience (Shanghai) Limited, a leading innovation-driven, clinical stage biotech, announced the appointment of Cong Lei, MD/PhD, as Senior Vice President of Clinical Development, where she will be responsible for formulating innovative product strategies and leading the global clinical development of a growing pipeline of small molecule cancer therapeutics.
Dr. Lei has extensive experience in clinical development of new molecular entities from IND filings to post launch Phase IV trials and is well versed with the global regulatory expectations across several therapeutic areas. Prior to joining Tyligand, Dr. Lei has previously served as Vice President of Clinical Development of Xuanzhu Biopharmaceutical Ltd.，Global Medical Director of Roche Asia Pacific R&D, Associate Medical Director of Novartis Pharma, Research Physician for Medical Affairs at Merck Serono and Bayer.
Dr. Lei studied at the School of Medicine of Xi 'an Jiaotong University, where she received her bachelor's degree in Clinical Medicine, PhD in Internal Medicine, and Medical Doctor's Degree (MD). She spent several years in clinical practice as an Attending Physician at Beijing Changyang Hospital affiliated with the Capital Medical University, before joining the pharmaceutical industry.
"The creativity in molecule design and passion for quality of Tyligand scientists have laid a solid foundation for developing medicines that can withstand the test of time and clinical trials”, said, Dr. Lei. “ I am very excited to join this world class team and look forward to collaborating with principal investigators across the globe to transform these outstanding molecules into safe and effective drugs for the patients" .
Tony Zhang, PhD, cofounder and CEO of Tyligand, said: "With the success of our preclinical portfolio and the imminent filing of several INDs, this quarter will witness the transformation of Tyligand from a swift discovery engine into a quality clinical stage biotech. Dr. Lei joins us at an opportune time for a large amount of challenging and exciting work ahead. We look forward to her experience, expertise and leadership to help forge a robust link between lab innovation and clinical outcomes, providing more accessible and more reliable treatment options for cancer patients across the world."
Tyligand Bioscience is a Shanghai based biotechnology company focusing on the discovery and development of novel small molecule therapeutics to help patients with cancer and autoimmune diseases. The company has built a 1st in class pipeline include a multi-kinase inhibitor to address drug resistance in solid tumors, a dual targeting immune agonist for oncology applications; and technology platforms for ADC, PROTAC, and modulation of phosphorylation status of signaling biomolecules. For more information, please visit www.tyligand.com.